Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimicrobial-associated acute hepatitis.

Susan C Nicholson1, C Douglas Webb, Robert C Moellering

  • 1Infectious Diseases, Bristol-Myers Squibb, Plainsboro, New Jersey 08536, USA. Susan.Nicholson@BMS.com

Pharmacotherapy
|June 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interest in Home Birth During the COVID-19 Pandemic: Analysis of Google Trends Data.

Journal of midwifery & women's health·2022
Same author

Impact of daptomycin resistance on Staphylococcus aureus virulence.

Virulence·2015
Same author

Tedizolid: a novel oxazolidinone for Gram-positive infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2013
Same author

Towards squalamine mimics: synthesis and antibacterial activities of head-to-tail dimeric sterol-polyamine conjugates.

Chemistry & biodiversity·2013
Same author

Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies.

Respiratory care·2013
Same author

Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.

Journal of opioid management·2012
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

This case review questions attributing acute hepatitis solely to gatifloxacin, highlighting other potential causes like amoxicillin-clavulanate. Physicians should consider broader differential diagnoses for drug-induced liver injury.

Area of Science:

  • Pharmacology
  • Hepatology
  • Infectious Diseases

Background:

  • Antimicrobial agents are frequently prescribed for common infections.
  • Drug-induced liver injury (DILI) is a significant concern in clinical practice.
  • Distinguishing the causative agent in polypharmacy cases can be challenging.

Observation:

  • A patient with chronic sinusitis developed acute hepatitis after receiving multiple antibiotics, including clarithromycin, levofloxacin, amoxicillin-clavulanate, and gatifloxacin.
  • The adverse event was attributed to gatifloxacin, despite the presence of other potential etiologies.
  • Hepatitis unrelated to Hepatitis A or B was not excluded.

Findings:

  • The case study's definitive attribution of hepatitis to gatifloxacin is questioned due to concurrent antibiotic use and other potential causes.

Related Experiment Videos

  • Extended amoxicillin-clavulanate therapy is a known risk factor for hepatotoxicity, which may manifest late.
  • The study suggests gatifloxacin may not be the sole or primary cause of the observed hepatitis.

    • Implications:

    • Clinicians should maintain a high index of suspicion for various causes of acute hepatitis when patients are on multiple medications.
    • A thorough differential diagnosis, considering all administered antimicrobials and other potential hepatotoxins, is crucial.
    • This case underscores the importance of robust evidence for attributing DILI to a specific drug, especially in complex therapeutic regimens.